AU2018204285A1 - Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders - Google Patents
Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disordersInfo
- Publication number
- AU2018204285A1 AU2018204285A1 AU2018204285A AU2018204285A AU2018204285A1 AU 2018204285 A1 AU2018204285 A1 AU 2018204285A1 AU 2018204285 A AU2018204285 A AU 2018204285A AU 2018204285 A AU2018204285 A AU 2018204285A AU 2018204285 A1 AU2018204285 A1 AU 2018204285A1
- Authority
- AU
- Australia
- Prior art keywords
- masp
- disorders
- compositions
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018204285A AU2018204285B2 (en) | 2012-06-18 | 2018-06-15 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
| AU2020202999A AU2020202999B2 (en) | 2012-06-18 | 2020-05-06 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661167P | 2012-06-18 | 2012-06-18 | |
| US61/661,167 | 2012-06-18 | ||
| AU2013277309A AU2013277309B2 (en) | 2012-06-18 | 2013-06-18 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
| PCT/US2013/046432 WO2013192240A2 (en) | 2012-06-18 | 2013-06-18 | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| AU2018204285A AU2018204285B2 (en) | 2012-06-18 | 2018-06-15 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013277309A Division AU2013277309B2 (en) | 2012-06-18 | 2013-06-18 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020202999A Division AU2020202999B2 (en) | 2012-06-18 | 2020-05-06 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018204285A1 true AU2018204285A1 (en) | 2018-07-05 |
| AU2018204285B2 AU2018204285B2 (en) | 2020-02-27 |
Family
ID=49769678
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013277309A Active AU2013277309B2 (en) | 2012-06-18 | 2013-06-18 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
| AU2018204285A Active AU2018204285B2 (en) | 2012-06-18 | 2018-06-15 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
| AU2020202999A Active AU2020202999B2 (en) | 2012-06-18 | 2020-05-06 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013277309A Active AU2013277309B2 (en) | 2012-06-18 | 2013-06-18 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020202999A Active AU2020202999B2 (en) | 2012-06-18 | 2020-05-06 | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20130344073A1 (en) |
| EP (5) | EP4119577A3 (en) |
| JP (5) | JP6445972B2 (en) |
| KR (4) | KR20220100997A (en) |
| CN (4) | CN109908352A (en) |
| AU (3) | AU2013277309B2 (en) |
| BR (1) | BR112014031522A2 (en) |
| CA (2) | CA2875567C (en) |
| CL (2) | CL2014003455A1 (en) |
| CY (1) | CY1124234T1 (en) |
| DK (1) | DK2861246T3 (en) |
| ES (1) | ES2864857T3 (en) |
| HR (1) | HRP20210559T1 (en) |
| HU (1) | HUE053727T2 (en) |
| IL (2) | IL236327B (en) |
| IN (1) | IN2015KN00015A (en) |
| LT (1) | LT2861246T (en) |
| MX (4) | MX381048B (en) |
| NZ (1) | NZ629473A (en) |
| PL (1) | PL2861246T3 (en) |
| PT (1) | PT2861246T (en) |
| RS (1) | RS61755B1 (en) |
| RU (2) | RU2019140356A (en) |
| SI (1) | SI2861246T1 (en) |
| WO (1) | WO2013192240A2 (en) |
| ZA (1) | ZA201500094B (en) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937046B2 (en) | 2008-09-22 | 2015-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
| KR20220044616A (en) | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Methods for treating conditions associated with masp-2 dependent complement activation |
| WO2014030750A1 (en) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | MOUSE FcγRII-SPECIFIC Fc ANTIBODY |
| US9217042B2 (en) * | 2012-10-23 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Method of reducing MACE in diabetic patients subsequent to stent placement |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| NZ629682A (en) | 2013-03-15 | 2017-03-31 | Omeros Corp | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| CN113621057A (en) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc region variants |
| US20160053023A1 (en) * | 2013-04-09 | 2016-02-25 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| CA2914566A1 (en) * | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
| SI3019240T1 (en) | 2013-07-09 | 2024-07-31 | Annexon, Inc. | Anti-complement factor c1q antibodies and uses thereof |
| SI3057993T1 (en) | 2013-10-17 | 2021-03-31 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| CN106687123A (en) * | 2014-06-05 | 2017-05-17 | 科罗拉多州大学评议会 | MAP44 polypeptides and natural antibody-based constructs and uses thereof |
| SG11201703667SA (en) | 2014-11-05 | 2017-06-29 | Annexon Inc | Humanized anti-complement factor c1q antibodies and uses thereof |
| US10639307B2 (en) | 2015-05-15 | 2020-05-05 | Children's Medical Center Corporation | Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides |
| CA2987976A1 (en) * | 2015-06-03 | 2016-12-08 | Coyne Ip Holdings, Llc | Methods for establishing threshold limits for a chemical or biological agent in a target species |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (en) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| KR102432062B1 (en) * | 2015-11-09 | 2022-08-12 | 오메로스 코포레이션 | Methods for treating conditions associated with masp-2 dependent complement activation |
| IL296130A (en) | 2015-11-24 | 2022-11-01 | Annexon Inc | Anti-complement factor c1q fab fragments and their uses |
| JP6682653B2 (en) * | 2016-01-05 | 2020-04-15 | ユニバーシティー オブ レスター | Methods for inhibiting fibrosis in a subject in need thereof |
| BR112018069732A2 (en) * | 2016-03-31 | 2019-02-05 | Omeros Corporation | methods for preventing, treating, reversing and / or delaying angiogenesis in a mammalian subject, for treating a subject suffering from ocular angiogenic disease or condition and for inhibiting tumor angiogenesis |
| JOP20170154B1 (en) * | 2016-08-01 | 2023-03-28 | Omeros Corp | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
| JOP20170170B1 (en) * | 2016-08-31 | 2022-09-15 | Omeros Corp | High concentration, low viscosity MASP-2 inhibitory antibody formulations, kits, and methods |
| AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2018186322A1 (en) * | 2017-04-03 | 2018-10-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-masp-1 antibodies and methods of use |
| EP3672994A4 (en) * | 2017-08-25 | 2021-06-02 | Omeros Corporation | HIGH CONCENTRATED, LOW VISCOSITY MASP-2 INHIBITOR ANTIBODY FORMULATIONS, KITS AND METHODS OF TREATMENT OF SUBJECTS WITH ATYPICAL HEMOLYTIC SYNDROME |
| EP4640703A2 (en) | 2017-11-14 | 2025-10-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| KR20200143459A (en) * | 2018-04-13 | 2020-12-23 | 추가이 세이야쿠 가부시키가이샤 | Anti-complement component antibodies and methods of use |
| KR20210016545A (en) | 2018-05-29 | 2021-02-16 | 오메로스 코포레이션 | MASP-2 inhibitors and methods of use |
| KR20210024003A (en) * | 2018-06-22 | 2021-03-04 | 오메로스 코포레이션 | MASP-2 inhibitory compositions and methods for the treatment of various thrombotic diseases and disorders |
| EP3847174A4 (en) | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS |
| JP7443375B2 (en) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | Macrocyclic compounds for the treatment of medical disorders |
| US11807627B2 (en) | 2018-09-25 | 2023-11-07 | Achillon Pharmaceuticals, Inc. | Morphic forms of complement factor D inhibitors |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| CA3123583A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| AU2020245434A1 (en) | 2019-03-22 | 2021-09-30 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| PH12021552817A1 (en) * | 2019-05-07 | 2022-09-28 | Bayer Ag | Masp inhibitory compounds and uses thereof |
| KR20220016865A9 (en) | 2019-05-15 | 2022-02-21 | 추가이 세이야쿠 가부시키가이샤 | Antigen Binding Molecules, Pharmaceutical Compositions, and Methods |
| WO2021113686A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| IL293551A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | Masp-2 inhibitor compounds, compositions comprising same and uses thereof |
| JP7721142B2 (en) | 2019-12-04 | 2025-08-12 | オメロス コーポレーション | MASP-2 inhibitors and methods of use |
| CA3159172A1 (en) | 2019-12-04 | 2021-06-10 | Michael Cicirelli | Masp-2 inhibitors and methods of use |
| CN112237630A (en) * | 2020-02-21 | 2021-01-19 | 中国人民解放军军事科学院军事医学研究院 | Application of MASP-2, coronavirus N protein or their combined substances in the preparation of drugs for diseases caused by coronavirus |
| TWI867422B (en) * | 2020-03-06 | 2024-12-21 | 美商奥默羅斯公司 | Methods of inhibiting masp-2 for the treatment and/or prevention of acute respiratory distress syndrome, pneumonia or some other pulmonary manifestation of influenza virus infection induced by influenza virus |
| MX2023001937A (en) | 2020-08-18 | 2023-04-05 | Omeros Corp | Monoclonal antibodies, compositions and methods for detecting complement factor d. |
| CN115215937B (en) | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | Anti-human MASP-2 antibody, preparation method and application thereof |
| US20230265215A1 (en) | 2021-12-10 | 2023-08-24 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| US12486322B2 (en) | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| CN114989259B (en) * | 2022-05-27 | 2023-06-09 | 成都佩德生物医药有限公司 | Small molecule peptide Ped4 and application thereof |
| US20240228499A1 (en) | 2022-11-30 | 2024-07-11 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| WO2024186766A1 (en) * | 2023-03-03 | 2024-09-12 | The City University Of New York | Use of extracellular vesicles as biomarkers for age-related macular degeneration |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| JP3218637B2 (en) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | Stable aqueous liposome suspension |
| JP2958076B2 (en) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| WO2001040451A2 (en) * | 1999-12-02 | 2001-06-07 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| WO2003077937A1 (en) * | 2002-03-15 | 2003-09-25 | Natimmune A/S | Pharmaceutical compositions comprising mannose binding lectin |
| CN100519643C (en) | 2002-07-19 | 2009-07-29 | 奥默罗斯公司 | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| CN1750844B (en) * | 2003-02-21 | 2010-09-08 | 健泰科生物技术公司 | Use of a lectin pathway-specific complement inhibitor in the preparation of a medicament for preventing or inhibiting tissue damage |
| ES2360399T3 (en) * | 2003-07-08 | 2011-06-03 | Umc Utrecht Holding B.V. | THERAPEUTIC USE OF LPI, AN INHIBITOR OF THE ROUTE OF LECTINES OF STAPHILOCOCICAL ORIGIN, IN INFLAMMATORY DISEASES. |
| CA2847677C (en) * | 2004-06-10 | 2018-05-01 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CN100518905C (en) * | 2004-11-02 | 2009-07-29 | 浙江欧美环境工程有限公司 | Turning type electric desalinization device |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AU2006283532B2 (en) | 2005-08-19 | 2012-04-26 | Abbvie Inc. | Dual variable domain immunoglobin and uses thereof |
| AU2006304804B2 (en) * | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
| AU2007223796B2 (en) * | 2006-03-08 | 2013-01-24 | Astellas Us Llc | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
| EP2152861B1 (en) | 2007-05-31 | 2017-03-22 | University of Washington | Inducible mutagenesis of target genes |
| CN109045296A (en) * | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | For treating the method and composition of complement associated disorders |
| KR20120105405A (en) * | 2009-06-23 | 2012-09-25 | 알렉시온 파마슈티칼스, 인코포레이티드 | Bispecific antibodies that bind to complement proteins |
| CA2767755C (en) * | 2009-07-17 | 2021-10-12 | Rigshospitalet | Inhibitors of complement activation |
| DK2488203T3 (en) * | 2009-10-16 | 2017-03-13 | Omeros Corp | METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| JP6148013B2 (en) * | 2010-03-05 | 2017-06-14 | リグショスピタレト | Chimera inhibitor molecule of complement activation |
| US8795973B2 (en) * | 2010-11-29 | 2014-08-05 | University of Leceister | Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof |
| KR20220044616A (en) * | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Methods for treating conditions associated with masp-2 dependent complement activation |
| SMT201800253T1 (en) * | 2012-04-06 | 2018-07-17 | Omeros Corp | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
| JOP20170154B1 (en) * | 2016-08-01 | 2023-03-28 | Omeros Corp | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
-
2013
- 2013-06-18 PT PT138073267T patent/PT2861246T/en unknown
- 2013-06-18 CA CA2875567A patent/CA2875567C/en active Active
- 2013-06-18 HU HUE13807326A patent/HUE053727T2/en unknown
- 2013-06-18 AU AU2013277309A patent/AU2013277309B2/en active Active
- 2013-06-18 SI SI201331873T patent/SI2861246T1/en unknown
- 2013-06-18 RU RU2019140356A patent/RU2019140356A/en unknown
- 2013-06-18 HR HRP20210559TT patent/HRP20210559T1/en unknown
- 2013-06-18 EP EP22177615.6A patent/EP4119577A3/en active Pending
- 2013-06-18 CN CN201811331359.1A patent/CN109908352A/en active Pending
- 2013-06-18 NZ NZ629473A patent/NZ629473A/en unknown
- 2013-06-18 CA CA3214532A patent/CA3214532A1/en active Pending
- 2013-06-18 KR KR1020227022627A patent/KR20220100997A/en not_active Ceased
- 2013-06-18 CN CN202210652007.6A patent/CN115040653A/en active Pending
- 2013-06-18 EP EP25210227.2A patent/EP4659763A3/en active Pending
- 2013-06-18 IN IN15KON2015 patent/IN2015KN00015A/en unknown
- 2013-06-18 EP EP13807326.7A patent/EP2861246B1/en active Active
- 2013-06-18 KR KR1020207027432A patent/KR102339315B1/en active Active
- 2013-06-18 BR BR112014031522A patent/BR112014031522A2/en not_active Application Discontinuation
- 2013-06-18 PL PL13807326T patent/PL2861246T3/en unknown
- 2013-06-18 WO PCT/US2013/046432 patent/WO2013192240A2/en not_active Ceased
- 2013-06-18 LT LTEP13807326.7T patent/LT2861246T/en unknown
- 2013-06-18 RU RU2015101230A patent/RU2709351C2/en active
- 2013-06-18 EP EP16150858.5A patent/EP3058951A1/en not_active Withdrawn
- 2013-06-18 EP EP21152111.7A patent/EP3878865A3/en not_active Withdrawn
- 2013-06-18 RS RS20210465A patent/RS61755B1/en unknown
- 2013-06-18 MX MX2014015715A patent/MX381048B/en unknown
- 2013-06-18 US US13/921,139 patent/US20130344073A1/en not_active Abandoned
- 2013-06-18 ES ES13807326T patent/ES2864857T3/en active Active
- 2013-06-18 CN CN201380044434.5A patent/CN104717975A/en active Pending
- 2013-06-18 KR KR1020207003537A patent/KR20200015952A/en not_active Ceased
- 2013-06-18 KR KR20157001304A patent/KR20150031298A/en not_active Ceased
- 2013-06-18 JP JP2015518524A patent/JP6445972B2/en active Active
- 2013-06-18 CN CN202410989581.XA patent/CN118924900A/en active Pending
- 2013-06-18 DK DK13807326.7T patent/DK2861246T3/en active
-
2014
- 2014-12-17 MX MX2024005899A patent/MX2024005899A/en unknown
- 2014-12-17 MX MX2020005700A patent/MX2020005700A/en unknown
- 2014-12-17 IL IL236327A patent/IL236327B/en active IP Right Grant
- 2014-12-17 MX MX2019012909A patent/MX2019012909A/en unknown
- 2014-12-18 CL CL2014003455A patent/CL2014003455A1/en unknown
-
2015
- 2015-01-07 ZA ZA2015/00094A patent/ZA201500094B/en unknown
-
2016
- 2016-12-22 CL CL2016003297A patent/CL2016003297A1/en unknown
-
2018
- 2018-06-15 AU AU2018204285A patent/AU2018204285B2/en active Active
- 2018-08-28 IL IL261436A patent/IL261436B/en unknown
- 2018-09-14 US US16/131,871 patent/US20190127484A1/en not_active Abandoned
- 2018-11-30 JP JP2018224961A patent/JP6771531B2/en active Active
-
2020
- 2020-05-06 AU AU2020202999A patent/AU2020202999B2/en active Active
- 2020-09-29 JP JP2020163180A patent/JP2021006546A/en active Pending
-
2021
- 2021-04-20 CY CY20211100342T patent/CY1124234T1/en unknown
- 2021-10-11 US US17/498,559 patent/US20220259325A1/en not_active Abandoned
-
2022
- 2022-04-01 JP JP2022062008A patent/JP2022084946A/en active Pending
-
2023
- 2023-09-26 US US18/474,862 patent/US20240254257A1/en not_active Abandoned
-
2024
- 2024-04-24 JP JP2024070206A patent/JP2024099699A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018204285A1 (en) | Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders | |
| DK2861246T3 (en) | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders | |
| EP3177732A4 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
| HUE041553T2 (en) | Methods and compositions for the treatment of monogenic diseases | |
| ME03042B (en) | Compounds and compositions for the treatment of parasitic diseases | |
| IL241264A0 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| EP3137116A4 (en) | Dendrimer compositions and their use in treatment of diseases of the eye | |
| IL239368A0 (en) | Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases | |
| EP3268007A4 (en) | Compositions and therapeutic methods for the treatment of complement-associated diseases | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| EP3160493A4 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| IL233639A0 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| EP3086809A4 (en) | Compositions and methods of treating ocular diseases | |
| EP2709632A4 (en) | Compositions and methods for the treatment of skin diseases | |
| EP3119387A4 (en) | Compositions for the treatment of dermatological diseases and disorders | |
| EP3043817A4 (en) | Methods and compositions for treatment of chlamydial infection and related diseases and disorders | |
| EP3107534A4 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
| EP2934501A4 (en) | Uses and methods for the treatment of liver diseases or conditions | |
| EP3065548A4 (en) | Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases | |
| HK40066378A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| HK40092382A (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| HK40093809A (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EP3129054A4 (en) | Methods and compositions for the treatment of ocular diseases and disorders | |
| HK40118621A (en) | Compositions and methods for inhibiting masp-1 and/or masp-2 and/or masp-3 |